Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study
Lopresti, A.L.ORCID: 0000-0002-6409-7839, Maes, M., Maker, G.L.
ORCID: 0000-0003-1666-9377, Hood, S.D. and Drummond, P.D.
ORCID: 0000-0002-3711-8737
(2014)
Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study.
Journal of Affective Disorders, 167
.
pp. 368-375.
*Subscription may be required
Abstract
Background
Curcumin, the principal curcuminoid derived from the spice turmeric, influences several biological mechanisms associated with major depression, namely those associated with monoaminergic activity, immune-inflammatory and oxidative and nitrosative stress pathways, hypothalamus-pituitary-adrenal (HPA) axis activity and neuroprogression. We hypothesised that curcumin would be effective for the treatment of depressive symptoms in individuals with major depressive disorder.
Methods
In a randomised, double-blind, placebo-controlled study, 56 individuals with major depressive disorder were treated with curcumin (500 mg twice daily) or placebo for 8 weeks. The primary measure was the Inventory of Depressive Symptomatology self-rated version (IDS-SR30). Secondary outcomes included IDS-SR30 factor scores and the Spielberger State-Trait Anxiety Inventory (STAI).
Results
From baseline to week 4, both curcumin and placebo were associated with improvements in IDS-SR30 total score and most secondary outcome measures. From weeks 4 to 8, curcumin was significantly more effective than placebo in improving several mood-related symptoms, demonstrated by a significant group x time interaction for IDS-SR30 total score (F1, 53=4.22, p=.045) and IDS-SR30 mood score (F1, 53=6.51, p=.014), and a non-significant trend for STAI trait score (F1, 48=2.86, p=.097). Greater efficacy from curcumin treatment was identified in a subgroup of individuals with atypical depression.
Conclusions
Partial support is provided for the antidepressant effects of curcumin in people with major depressive disorder, evidenced by benefits occurring 4 to 8 weeks after treatment.
Limitations
Investigations with larger sample sizes, over extended treatment periods, and with varying curcumin dosages are required.
Item Type: | Journal Article |
---|---|
Murdoch Affiliation(s): | School of Psychology and Exercise Science School of Veterinary and Life Sciences |
Publisher: | Elsevier |
Copyright: | Elsevier |
Notes: | Available online 11 June 2014 |
URI: | http://researchrepository.murdoch.edu.au/id/eprint/23170 |
![]() |
Item Control Page |
Downloads
Downloads per month over past year